LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.13

-0.14%
HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

At a Glance

Live Snapshot
Market Cap$223.56M
EPS-2.8500
P/E Ratio-5.61
Earnings Date07/29/2026

lenz

Net Cash Provided by Financing Activities

Last Annual Value

149.75M

3-Year CAGR

531%

5-Year CAGR

38%

10-Year CAGR

%

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

LENZ · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
149.75M
22.9%-18.5%N/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
137.81M
18.5%2.7%39.0%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
107.33M
110.1%15.8%25.9%
104.60M
147.5%14.5%N/A
5.72M
-42.8%-47.0%-7.6%
2.27M
-81.6%-45.8%6.8%
-16.50M
N/AN/AN/A
151.51M
513.9%-10.9%N/A
8.10M
74.0%-51.8%N/A
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Fair Value Envelope

LENZ · NASDAQ

Our analysis suggests that LENZ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.13, this represents a potential HIDDEN relative to our calculated worth for LENZ Therapeutics, Inc..

Intrinsic Value
Current Price: $7.13